Virogen Biotechnology Inc.
- Biotech or pharma, therapeutic R&D
Virogen Biotechnology Inc. is a clinical-stage biotechnology company advancing VG712, a first-in-class anti-CD3 immunotoxin that rapidly depletes dysfunctional T cells to reset the immune system. By disrupting the tumor microenvironment and enabling the regeneration of functional T cells, VG712 restores durable anti-tumor immunity.
In a U.S. Phase I trial, a simple four-day treatment with VG712 led to complete remission in several late-stage cancer patients, providing clinical validation for the concept of immunological reset. VG712 also shows strong potential in immune tolerance for organ transplantation, graft-versus-host disease (GvHD), lymphodepletion prior to cell therapy, and autoimmune disorders. In a preclinical aGvHD model, VG712 achieved over 90% survival, compared to 0% with standard of care.
Virogen has received FDA clearance for a pivotal Phase II trial for CTCL, with additional INDs pending for aGvHD and renal transplant.
The company is targeting a BLA submission in 2028.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}